ResearcherQueen's UniversityActive in the last 2 years
Myron R. Szewczuk
Matched on ORCID iD 0000-0001-8471-5481; OpenAlex author ID A5053078335.
Their work
- Papers
- 8 (first author 1, last author 5)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 7
2013: 1 paper · 2014: 1 paper · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: none · 2022: 1 paper · 2023: none · 2024: none · 2025: none · 2026: 1 paper
Papers 8
- Sex Hormone Estrone Sulfate Serendipitously Downregulates Intercellular Tunneling Nanotube Conduits, EMT, and Migration in Breast and Pancreatic Cancer Cells. Last author DOI 10.3390/cancers18203354↗
- Next Generation of Cancer Drug Repurposing: Therapeutic Combination of Aspirin and Oseltamivir Phosphate Potentiates Gemcitabine to Disable Key Survival Pathwa… Last author DOI 10.3390/cancers14061374↗
- Novel Molecular Mechanism of Aspirin and Celecoxib Targeting Mammalian Neuraminidase-1 Impedes Epidermal Growth Factor Receptor Signaling Axis and Induces Apop… Last author DOI 10.2147/dddt.s264122↗
- Oseltamivir phosphate released from injectable Pickering emulsions over an extended term disables human pancreatic cancer cell survival. Co-author DOI 10.18632/oncotarget.24339↗
- Combinatorial and sequential delivery of gemcitabine and oseltamivir phosphate from implantable poly(d,l-lactic-co-glycolic acid) cylinders disables human panc… Co-author DOI 10.2147/dddt.s137934↗
- Sialylation transmogrifies human breast and pancreatic cancer cells into 3D multicellular tumor spheroids using cyclic RGD-peptide induced self-assembly. Last author DOI 10.18632/oncotarget.11868↗
- Therapeutic targeting of Neu1 sialidase with oseltamivir phosphate (Tamiflu®) disables cancer cell survival in human pancreatic cancer with acquired chemoresis… First author DOI 10.2147/ott.s55344↗
- A novel epidermal growth factor receptor-signaling platform and its targeted translation in pancreatic cancer. Last author DOI 10.1016/j.cellsig.2013.08.008↗
Closest collaborators
The 7 strongest of 7 ranked by shared papers, trials and grants, with recent and small-team work weighing most.
- Izzah Wahab · 1 shared paper, 2026
- Bessi Qorri · 2 shared papers, 2020–2022
- Paper Next Generation of Cancer Drug Repurposing: Therapeutic Combination of Aspirin and Oseltamivir Phosphate Potentiates Ge… DOI 10.3390/cancers14061374↗
- Paper Novel Molecular Mechanism of Aspirin and Celecoxib Targeting Mammalian Neuraminidase-1 Impedes Epidermal Growth Factor … DOI 10.2147/dddt.s264122↗
- Ronald J. Neufeld · 4 shared papers, 2014–2018
- Paper Oseltamivir phosphate released from injectable Pickering emulsions over an extended term disables human pancreatic canc… DOI 10.18632/oncotarget.24339↗
- Paper Combinatorial and sequential delivery of gemcitabine and oseltamivir phosphate from implantable poly(d,l-lactic-co-glyc… DOI 10.2147/dddt.s137934↗
- Paper Sialylation transmogrifies human breast and pancreatic cancer cells into 3D multicellular tumor spheroids using cyclic … DOI 10.18632/oncotarget.11868↗
- Stephanie Allison-Logan · 2 shared papers, 2014–2017
- Paper Combinatorial and sequential delivery of gemcitabine and oseltamivir phosphate from implantable poly(d,l-lactic-co-glyc… DOI 10.2147/dddt.s137934↗
- Paper Therapeutic targeting of Neu1 sialidase with oseltamivir phosphate (Tamiflu®) disables cancer cell survival in human pa… DOI 10.2147/ott.s55344↗
- Kurt Wood · 1 shared paper, 2018
- Roman Akasov · 1 shared paper, 2016
- Alanna M. Gilmour · 1 shared paper, 2013
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (the fewest links first, then the links with the most shared work). Built from public records only; no contact details are kept.